GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
1. FDA accepted GSK’s marketing application for depemokimab in two conditions. 2. Depemokimab shows significant improvements in CRSwNP and asthma treatment. 3. Phase 3 trials met primary endpoints for nasal obstruction and polyp size. 4. PDUFA date set for Dec. 16, 2025, indicating potential market entry. 5. GSK stock rose 2.04% following the announcement.